Company Filing History:
Years Active: 2023
Title: Yoon-Chi Han: Innovator in Antibody-Drug Conjugate Technology
Introduction: Yoon-Chi Han is an accomplished inventor based in New York, NY, whose work has significantly contributed to the field of biopharmaceuticals. With a keen focus on antibody-drug conjugate technology, Yoon-Chi has developed innovative solutions aimed at treating conditions associated with CD123 expression, including various types of cancer and autoimmune diseases.
Latest Patents: Yoon-Chi Han holds a patent titled "Antibodies and antibody-drug conjugates specific for CD123 and uses thereof." This invention encompasses antibodies that specifically bind to the CD123 target. In addition to the antibodies themselves, the patent also includes immunoconjugates, such as antibody-drug conjugates (ADCs), methods for obtaining these antibodies, and therapeutic approaches for utilizing them in treatments. The research highlights the potential of these antibodies and ADCs in addressing serious health conditions linked to CD123.
Career Highlights: Yoon-Chi is currently employed at Pfizer Corporation, one of the leading pharmaceutical companies globally. Her role at Pfizer allows her to leverage her expertise in pharmaceuticals, contributing to innovative research and development in the biopharmaceutical sector.
Collaborations: During her career, Yoon-Chi has collaborated with notable colleagues such as Manoj Baburao Charati and Madan Katragadda. These partnerships have fostered a collaborative environment that enhances innovation and accelerates the development of new therapeutic solutions.
Conclusion: Yoon-Chi Han exemplifies the spirit of innovation in the biopharmaceutical industry. Through her groundbreaking patent and collaborative efforts, she is making significant strides toward advancing treatment options for diseases associated with CD123. Her work not only represents a valuable contribution to science but also holds promise for improving patient care in the future.